Clicky

GLENMARK PHARMACEUTICALS LTD.(GLENMARK)

Description: Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830, an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISC 17536, an oral transient receptor potential ankyrin-1 antagonist, which has completed Phase 2a clinical trial for the treatment of diabetic peripheral neuropathy; ISB 1302, a HER2 X CD3 beat bispecific antibody, which is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; ISC XXXXX, an HPK1 inhibitor for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma t for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India.


Keywords: Medicine Pharmaceutical Pharmaceutical Products Immunology Active Pharmaceutical Ingredients Monoclonal Antibodies Cancer Treatment Atopic Dermatitis Allergic Rhinitis Her2 Markets Pharmaceutical Products Diabetic Peripheral Neuropathy Cd38 Ox40 Relapsed/Refractory Multiple Myeloma

Home Page: www.glenmarkpharma.com

Glenmark House
Mumbai, 400099
India
Phone: 91 22 4018 9999


Officers

Name Title
Mr. Glenn Mario Saldanha Chairman, MD & CEO
Mr. V. S. Mani Global CFO & Exec. Director
Mr. Harish Vinayak Kuber Company Sec. & Compliance Officer
Ms. Cherylann Maria Pinto Exec. Director of Corp. Services & Exec. Director
Dr. Darshan B. Makhey Pres & Chief Quality Officer
Mr. Jayaram Philkana Pres & Global Chief HR Officer
Mr. Sriram Venkatasubramanian Pres & Head of Global Operations and Supply Chain
Ms. Meera Vanjari Sr. VP of Legal & Gen. Counsel
Udaykumar Murthy Sr. Mang. of Corp. Communications
Mr. P. Chinnapa Reddy Exec. VP and Global Head Bus. Devel.

Exchange: BSE

Country: IN

Currency: Indian Rupee (INR)

Forward PE: 14.9031
Trailing PE: 13.0313
Price-to-Book MRQ: 1.2951
Price-to-Sales TTM: 1.0219
IPO Date:
Fiscal Year End: March
Full Time Employees: 14000
Back to stocks